Free tool
FAERS Monitor: Giapreza
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209360 or its brand name (Giapreza, Angiotensin Ii Acetate). Reports on generic versions are filed under their own applications.
Reports
300
Serious
273
91% of reports
Hospitalization
116
Death reported
95
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective72
- off label use31
- death26
- acute kidney injury25
- toxicity to various agents19
- distributive shock17
- peripheral ischaemia17
- hypotension16
- overdose16
- intestinal ischaemia15
- cardiac arrest13
- cardiogenic shock12
- bradycardia11
- intentional overdose11
- deep vein thrombosis10
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 7 |
| 2012 | 13 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 12 |
| 2019 | 29 |
| 2020 | 18 |
| 2021 | 30 |
| 2022 | 38 |
| 2023 | 43 |
| 2024 | 19 |
| 2025 | 34 |
| 2026 | 34 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,859 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| distributive shockSignal | 17 | 530.2 | 333.5 | 8,396 |
| peripheral ischaemiaSignal | 17 | 293.1 | 184.5 | 4,642 |
| intestinal ischaemiaSignal | 15 | 191.5 | 116.9 | 2,649 |
| cardiogenic shockSignal | 12 | 58.7 | 33.7 | 624 |
| bradycardiaSignal | 11 | 14.5 | 8.1 | 126 |
| intentional overdoseSignal | 11 | 12.0 | 6.7 | 101 |
| acute kidney injurySignal | 25 | 11.5 | 7.9 | 230 |
| cardiac arrestSignal | 13 | 11.0 | 6.5 | 109 |
| deep vein thrombosisSignal | 10 | 10.8 | 5.9 | 80 |
| toxicity to various agentsSignal | 19 | 7.9 | 5.1 | 109 |
| hypotensionSignal | 16 | 5.6 | 3.5 | 56 |
| overdoseSignal | 16 | 5.2 | 3.2 | 51 |
| drug ineffectiveSignal | 72 | 3.8 | 3.1 | 158 |
| off label useSignal | 31 | 2.5 | 1.8 | 27 |
| deathSignal | 26 | 2.1 | 1.5 | 15 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.